Ir para o conteúdo principal

Anika Therapeutics (NASDAQ: ANIK) — Perfil da empresa, notícias e dados financeiros

Logo de Anika Therapeutics
ANIK Anika Therapeutics
Anika Therapeutics primary media
Perfil da empresa

Anika Therapeutics

Anika Therapeutics (NASDAQ:ANIK) focuses on developing, manufacturing, and commercializing advanced solutions for joint health, pain management, and tissue regeneration. This company's mission is to improve the lives of patients worldwide by offering innovative therapies that advance the standard of care. Anika Therapeutics' portfolio includes hyaluronic acid products for osteoarthritis pain treatment, surgical aids in the orthopedic and other healthcare markets, and therapeutic products for tissue repair and regeneration. The company is committed to scientific excellence and operates with a vision to become a leader in delivering solutions that address unmet medical needs in its targeted markets. Through its dedication to innovation, Anika Therapeutics aims to achieve sustained growth and enhance shareholder value by expanding its product offerings and reaching more patients globally.

Resumo

Public USParticipação acionária
1983Ano de fundação
357Funcionários
Bedford, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de Anika Therapeutics

  • Orthovisc and Monovisc - hyaluronic acid-based therapies for pain relief in osteoarthritis patients.
  • Cingal - combines hyaluronic acid with a steroid to provide longer-lasting pain relief from osteoarthritis.
  • Hyalofast - a biodegradable support for hyaluronic acid, aiding in cartilage regeneration.
  • Tactoset - an injectable, bone substitute for repairing bone defects.
  • Hyalobarrier - a gel used to prevent post-surgical adhesions.
  • Rotium Bioresorbable Wick - designed to enhance the repair of rotator cuff injuries by improving tendon healing.

equipe executiva do Anika Therapeutics

  • Cheryl Renee BlanchardExecutive Chair
  • Stephen D. GriffinPresident, Principal Financial Officer, CEO & Director
  • Ian W. McLeodSenior VP, Chief Accounting Officer & Treasurer
  • Matthew HallExecutive Director of Corporate Development & Investor Relations
  • Lisa FunicielloVP & Chief Human Resources Officer
  • Ben JosephSenior Vice President of Commercial
  • Mira LeiwantSenior Vice President of Regulatory, Quality & Clinical Affairs

Principais indicadores financeiros

Resultados divulgados pela Anika Therapeutics, em USD.

Cap. de mercado
285,7 mi
Receita (TTM)
120,7 mi
P/L
—
LPA (diluído, TTM)
-0.2
Dividend yield
—
Margem de lucro
-3.1%
Receita e lucro anuais da Anika Therapeutics
Fim do ano fiscalReceitaResultado operacionalLucro líquido
112,8 mi-11,1 mi-10,9 mi
119,9 mi-5,1 mi-56,4 mi
120,8 mi844 mil-82,7 mi
156,2 mi-19,4 mi-14,9 mi